Skip to content

Clinical Efficacy and Brain Network Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation in Treating Neuropathic Pain after Spinal Cord Injury

Clinical Efficacy and Brain Network Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation in Treating Neuropathic Pain after Spinal Cord Injury

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127559
Enrollment
Unknown
Registered
2026-07-02
Start date
2026-03-10
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic Pain after Spinal Cord Injury

Interventions

Control group:Transcutaneous vagus nerve electrical stimulation (sham stimulation)
Experimental group:transcutaneous auricular vagus nerve stimulation (active stimulation)

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for NP, with motor and sensory dysfunction in the spinal cord innervated areas below the level of injury, and patient-reported pain such as burning pain, allodynia, stabbing pain, etc; 2.Stable vital signs, clear consciousness, ability to express themselves clearly, and pain occurring after SCI; 3.No serious complications; 4.Patients have given informed consent and signed the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Individuals with mental illness or other serious comorbidities; 2.Those with severe cardiac, cerebral, or other internal medical conditions; 3.Individuals with contraindications such as having a cardiac pacemaker, cochlear implant, or any other metallic foreign bodies or implanted electronic devices, or those with other examination abnormalities that, in the investigator's judgment, render them unsuitable for participation in this trial;

Design outcomes

Primary

MeasureTime frame
Short-Form McGill Pain Questionnaire;

Secondary

MeasureTime frame
Activities of Daily Living (ADL) scale score;Somatosensory Evoked Potentials;Leeds Assessment of Neuropathic Symptoms and Signs;Interleukin-6;Generalized Anxiety Disorder-7 Score;Douleur Neuropathique 4 questions;Motor Evoked Potentials (MEP);Functional Near-Infrared Spectroscopy (fNIRS);Patient Health Questionnaire-9 (PHQ-9);Chinese version of the World Health Organization Quality of Life Brief Scale (WHOQOL-BREF);

Countries

China

Contacts

Public ContactYinxu Wang

Affiliated Hospital of North Sichuan Medical College

34089681@qq.com+86 817 2598262

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026